Topic: Polymeric nanoparticles

Therapies for neurodegenerative disease are limited in efficacy and tolerability, largely due to poor drug penetration across the BBB and off-target effects. Polymeric nanoparticles (NPs) are advantageous for brain drug delivery due to their safety profiles, drug-loading capacity, controlled-release properties and potential for drug repurposing. The aim of this work was to perform in vitro screening of NPs synthesised using the FDA-approved poly(lactic co-glycolic acid) (PLGA) polymer as drug delivery vehicles in primary rat neurons and glia as a prerequisite for further assessment in animal m

Cancer remains a significant challenge in the medical field (Siegel et al., 2012). Conventional treatments frequently have serious side effects that lower patients' quality of life and cannot totally eradicate the disease (Hendijani, 2015). Additionally, neural progenitor cells might be adversely affected by chemotherapeutic drugs, extinguishing any possibility of nervous tissue regeneration (Dietrich et al., 2006). This emphasizes the importance of precisely targeting cancer cells while preserving healthy brain cells. This work aims at addressing this challenge through the development of poly